Literature DB >> 25027418

Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance.

Charlie A McCaslin1, Daniela N Petrusca2, Gregory G Anderson3, Irina Petrache2,4, Christophe Poirier2, Karina A Serban2.   

Abstract

Pseudomonas aeruginosa infection is a hallmark of lung disease in cystic fibrosis. Acute infection with P. aeruginosa profoundly inhibits alveolar macrophage clearance of apoptotic cells (efferocytosis) via direct effect of virulence factors. During chronic infection, P. aeruginosa evades host defense by decreased virulence, which includes the production or, in the case of mucoidy, overproduction of alginate. The impact of alginate on innate immunity, in particular on macrophage clearance of apoptotic cells is not known. We hypothesized that P. aeruginosa strains that exhibit reduced virulence impair macrophage clearance of apoptotic cells and we investigated if the polysaccharide alginate produced by mucoid P. aeruginosa is sufficient to inhibit alveolar macrophage efferocytosis. Rat alveolar or human peripheral blood monocyte (THP-1)-derived macrophage cell lines were exposed in vitro to exogenous alginate or to wild type or alginate-overproducing mucoid P. aeruginosa prior to challenge with apoptotic human Jurkat T-lymphocytes. The importance of LPS contamination and that of structural integrity of alginate polymers was tested using alginate of different purities and alginate lyase, respectively. Alginate inhibited alveolar macrophage efferocytosis in a dose- and time-dependent manner. This effect was augmented but not exclusively attributed to lipopolysaccharide (LPS) present in alginates. Alginate-producing P. aeruginosa inhibited macrophage efferocytosis by more than 50%. A mannuronic-specific alginate lyase did not restore efferocytosis inhibited by exogenous guluronic-rich marine alginate, but had a marked beneficial effect on efferocytosis of alveolar macrophages exposed to mucoid P. aeruginosa. Despite decreased virulence, mucoid P. aeruginosa may contribute to chronic airway inflammation through significant inhibition of alveolar clearance of apoptotic cells and debris. The mechanism by which mucoid bacteria inhibit efferocytosis may involve alginate production and synergy with LPS, suggesting that alginate lyase may be an attractive therapeutic approach to airway inflammation in cystic fibrosis and other chronic obstructive pulmonary diseases characterized by P. aeruginosa colonization.
Copyright © 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alginate lyase; Cystic fibrosis; Efferocytosis; Macrophage; Mucoid; Phagocytosis; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2014        PMID: 25027418      PMCID: PMC4637177          DOI: 10.1016/j.jcf.2014.06.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  43 in total

Review 1.  Keeping their options open: acute versus persistent infections.

Authors:  S Furukawa; S L Kuchma; G A O'Toole
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

2.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

Authors:  R L Henry; C M Mellis; L Petrovic
Journal:  Pediatr Pulmonol       Date:  1992-03

3.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

4.  Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system.

Authors:  D Dacheux; I Attree; C Schneider; B Toussaint
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

6.  Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis.

Authors:  Nadine Hoffmann; Thomas Bovbjerg Rasmussen; Peter Østrup Jensen; Charlotte Stub; Morten Hentzer; Søren Molin; Oana Ciofu; Michael Givskov; Helle Krogh Johansen; Niels Høiby
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

7.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

8.  Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate.

Authors:  Nasim Kashef; Qorban Behzadian-Nejad; Shahin Najar-Peerayeh; Kamran Mousavi-Hosseini; Mohammad Moazzeni; Gholamreza Esmaeeli Djavid
Journal:  J Med Microbiol       Date:  2006-10       Impact factor: 2.472

9.  Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity.

Authors:  R J Mrsny; B A Lazazzera; A L Daugherty; N L Schiller; T W Patapoff
Journal:  Pulm Pharmacol       Date:  1994-12

10.  Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate.

Authors:  D E Ohman; A M Chakrabarty
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

View more
  9 in total

1.  Alpha-1 antitrypsin supplementation improves alveolar macrophages efferocytosis and phagocytosis following cigarette smoke exposure.

Authors:  Karina A Serban; Daniela N Petrusca; Andrew Mikosz; Christophe Poirier; Angelia D Lockett; Lauren Saint; Matthew J Justice; Homer L Twigg; Michael A Campos; Irina Petrache
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

2.  Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.

Authors:  Laura J Rojas; Mohamad Yasmin; Jacquelynn Benjamino; Steven M Marshall; Kailynn J DeRonde; Nikhil P Krishnan; Federico Perez; Andrew A Colin; Monica Cardenas; Octavio Martinez; Armando Pérez-Cardona; Daniel D Rhoads; Michael R Jacobs; John J LiPuma; Michael W Konstan; Alejandro J Vila; Andrea Smania; Andrew R Mack; Jacob G Scott; Mark D Adams; Lilian M Abbo; Robert A Bonomo
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.752

3.  In Vitro Synergistic Inhibitory Activity of Natural Alkaloid Berberine Combined with Azithromycin against Alginate Production by Pseudomonas aeruginosa PAO1.

Authors:  Zhijing Zhao; Mengyu Guo; Xiaona Xu; Yue Hu; Dongmei Liu; Chunxia Wang; Xinwei Liu; Yongwei Li
Journal:  Oxid Med Cell Longev       Date:  2022-09-10       Impact factor: 7.310

4.  Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine.

Authors:  Saeid Azimi; Leila Safari Zanjani
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

Review 5.  The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation.

Authors:  Aleksander M Grabiec; Tracy Hussell
Journal:  Semin Immunopathol       Date:  2016-03-08       Impact factor: 9.623

Review 6.  Gender differences in bronchiectasis: a real issue?

Authors:  Celine Vidaillac; Valerie F L Yong; Tavleen K Jaggi; Min-Min Soh; Sanjay H Chotirmall
Journal:  Breathe (Sheff)       Date:  2018-06

Review 7.  Alveolar Macrophages in the Resolution of Inflammation, Tissue Repair, and Tolerance to Infection.

Authors:  Benoit Allard; Alice Panariti; James G Martin
Journal:  Front Immunol       Date:  2018-07-31       Impact factor: 7.561

8.  Coping with Environmental Eukaryotes; Identification of Pseudomonas syringae Genes during the Interaction with Alternative Hosts or Predators.

Authors:  Federico Dorati; Glyn A Barrett; Maria Sanchez-Contreras; Tanya Arseneault; Mateo San José; David J Studholme; Jesús Murillo; Primitivo Caballero; Nicholas R Waterfield; Dawn L Arnold; Liz J Shaw; Robert W Jackson
Journal:  Microorganisms       Date:  2018-04-21

Review 9.  Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections.

Authors:  Luke L Proctor; Whitney L Ward; Conner S Roggy; Alexandra G Koontz; Katie M Clark; Alyssa P Quinn; Meredith Schroeder; Amanda E Brooks; James M Small; Francina D Towne; Benjamin D Brooks
Journal:  Antibiotics (Basel)       Date:  2021-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.